Results for this period
Third quarter1 June 2025–28 February 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
In the pharmaceuticals business, sales of imported active pharmaceutical ingredients increased against a backdrop of expanding demand for existing products, while sales of in-house-manufactured active pharmaceutical ingredients and isotopes remained firm. In the health foods business, orders for OEM jelly products remained firm, and the factory operating rate also remained high. In the chemicals business, results benefited from the revitalization of the semiconductor-related market, expansion into the market for the power industry, and deliveries of in-house-manufactured equipment. The cost ratio also improved as sales volumes of high-value-added products increased.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 June 2025–28 February 2026 |
| Net Sales | ¥5,651 million (YoY +16.8%) |
| Operating profit | ¥546 million (YoY +59.1%) |
| Ordinary income | ¥514 million (YoY +44.8%) |
| Profit attributable to owners of the parent | ¥337 million (YoY +35.7%) |
| Net income per share | ¥84.11 |
| Equity ratio | End of the current fiscal period 43.4 / End of previous period 46.6 |
| Total assets | ¥6,420 million |
| Net assets | ¥2,787 million |
| Full-year earnings forecast | Net Sales ¥7,700 million (YoY +15.7%) / Operating profit ¥700 million (YoY +62.0%) / Ordinary income ¥660 million (YoY +53.5%) / Net income ¥470 million (YoY +94.8%) |
| Revision to Earnings Forecast | Net Sales Not disclosed → ¥7,700 million / Operating profit Not disclosed → ¥700 million / Ordinary income Not disclosed → ¥660 million / Net income Not disclosed → ¥470 million |
| Annual Dividend Forecast | ¥25 → ¥26 |
| Segment revenue | Pharmaceuticals Business ¥2,793,518 thousand (YoY +20.6%), Health Foods Business ¥931,947 thousand (YoY +18.0%), Chemicals Business ¥1,926,184 thousand (YoY +11.2%) |
| Segment profit | Pharmaceuticals Business ¥439,593 thousand (YoY +37.0%), Health Foods Business ¥27,266 thousand (YoY +409.2%), Chemicals Business ¥79,573 thousand (YoY +365.6%) |
| Depreciation and amortization | ¥135,643 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥0 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥840 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 4,095,500 Shares |
| Treasury Shares at Period-End | 70,426 Shares |
| Factors Behind Changes in Business Performance | In the pharmaceuticals business, sales of imported active pharmaceutical ingredients increased against a backdrop of expanding demand for existing products, while sales of in-house-manufactured active pharmaceutical ingredients and isotopes remained firm. In the health foods business, orders for OEM jelly products remained firm, and the factory operating rate also remained high. In the chemicals business, results benefited from the revitalization of the semiconductor-related market, expansion into the market for the power industry, and deliveries of in-house-manufactured equipment. The cost ratio also improved as sales volumes of high-value-added products increased. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The full-year forecasts were revised based on recent business trends and other factors. In the pharmaceuticals business, sales of imported active pharmaceutical ingredients increased against a backdrop of expanding demand for existing products. In the health foods business, orders for OEM jelly products remained firm. In the chemicals business, results benefited from the revitalization of the semiconductor-related market, expansion into the market for the power industry, and deliveries of in-house-manufactured equipment.